In 2007, Deloitte Access Economics prepared a report for Parkinson’s report ‘Living with Parkinson’s disease: Challenges and positive steps for the future’ was published, this report was updated in 2011. A new revised and updated version has now been produced: ‘Living with Parkinson’s Disease: An updated economic analysis 2014’. The key findings of the 2014 report include:
- Conservative estimates indicate there are just under 82,000 (2018 est.) people living with Parkinson’s in Australia making it the most common major movement disorder and second highest prevalence neurodegenerative condition with only dementia exceeding it in the number of deaths. (UPDATE – the most recent research indicates that there may be more than 110,000 people living with Parkinson’s in Australia.)
- One in every 308 people (2018 est.) in Australia lives with Parkinson’s.
- On average, 37 new cases are diagnosed every day and 13,500 new cases will be diagnosed in 2018.
- Of the 82,000 people living with Parkinson’s around 18% are of working age.
- As Parkinson’s prevalence increases threefold after the age of 65, the growth rate in number of people living with Parkinson’s is expected to increase dramatically as the Australian population ages. It is estimated that the growth rate will average 4% over the next 20 years compared to a general population growth rate of just over 1%.
- In 2014 prevalence of Parkinson’s was higher than many cancers including breast cancer, colorectal, stomach, liver and pancreatic cancer, lymphoma and leukaemia, kidney and bladder, uterine, cervical, and ovarian, and lung cancer.
- The average time from onset to death is 12.4 years although many people who are diagnosed early in life will live with Parkinson’s for many more years than this.
- For someone living with Parkinson’s for 12 years, the average lifetime financial cost is around $161,300, which is on par with the average lifetime financial cost of cancer ($145,000).
- People living with Parkinson’s are more than 5 times more likely to be in residential aged care facilities than the general population.
- The total economic cost of Parkinson’s in 2014 was over $9.9 billion for the year 2014. This represents an increase of $3.2 billion since 2005, or 46%.
- The burden of care borne by carers has increased over 14 times the value in 2005.
- Overall the direct financial cost of Parkinson’s has increased by 103% since 2005 and the burden of disease cost has increased by 42% in the same period.
- There are cost effective interventions that can assist People living with Parkinson’s to achieve a higher quality of life whilst at the same time reducing the cost to the community of this condition.
Parkinson’s Australia has developed an Action Framework in reponse to the Deloitte Report – for the first time Parkinson’s should be made a focus of national action through the Commonwealth and States by:
- Recognition of Parkinson’s as a National Health Priority Area;
- Investment in better care and support for people living with Parkinson’s through access to Parkinson’s nurse Specialists and equitable access to medications and therapies;
- Investment and capacity building in Parkinson’s research.
- Investment in upskilling the workforce to enable timely diagnosis, better care and support of people living with Parkinson’s;
Without action, Parkinson’s remains a burden on society, on individuals and on carers.